 Anchiano Therapeutics Ltd. ANCN Anchiano or the Company, a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today reported that Anchiano Therapeutics, Inc., the Companys U.S. subsidiary, has entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharmaceuticals, LLC ADT to develop novel small-molecule inhibitors of RAS and PDE10β-catenin. This collaboration reflects Anchianos ongoing strategy to grow a pipeline beyond its pivotal-stage asset, inodiftagene vixteplasmid, with programs that have the potential to address significant clinical needs, while leveraging Anchianos expertise in small-molecule oncology development. 